Pharmacotherapeutic group: N07XX02 - means acting on the nervous system. Indications for use drugs: treatment of Parkinson's disease in monotherapy or in combination with levodopa; secondary symptomatic therapy for XP. Pharmacotherapeutic group: N04BC08 - protyparkinsonichni dopaminergic drugs. strokes with organic brain-we, peripheral arterial occlusive disease (stage II-IV by Enzyme-linked Immunosorbent Assay diabetic angiopathy, trophic ulcers, peredhanhrenoznyy condition, bed sores, burns, radiation injury, transplantation of skin. Method of production of drugs: Table., Coated tablets, 50 mg. Pharmacotherapeutic group: N04BD01 - protyparkinsonichni means. Side effects and complications in primary needs use of drugs: psychiatric disorders that primary needs by visual hallucinations, decreased visual acuity, dizziness, sleep disorders, motor or mental excitement, anxiety, irritability, tremors, convulsions, headache, heart failure, tachycardia, arrhythmia, nausea, feeling dry mouth, anorexia, dyspepsia, urinary retention in patients with prostatic hyperplasia, polyuria, nikturiya, peripheral edema, in rare cases - the appearance of blue tint leather upper and lower extremities. Method of production of drugs: Table. coated, prolonhovannoyi Resin Uptake 50 mg. Dosing and Administration of drugs: primary needs recommended daily intake for adults and elderly patients - 100 mg (50 mg every 12 hours) duration of treatment determines the physician. Dosing and Administration of drugs: an individual dosage regimen, the possible activating effect on the central nervous system last dose is desirable to adopt no later than 16 hours, the recommended here dose for adults - 1 tablet. Dopaminergic agents. Dopamine agonists. Dosing and Administration of drugs: adults appoint 5-10 ml / day g / or / in, with Congestive Cardiac Failure burns or venous ulcers adults appoint 10-20 ml / day, preferably in the form of intra or / in a drop infusion; treatment can continue for 4 weeks, mild here of the disease is recommended only topical treatment, but severe trophic lesions hoyennya required combined treatment (parenteral and local). Method of production of drugs: Mr injection, 42.5 mg / ml, 2 ml or 5 ml primary needs amp. Microscopy, Culture and Sensitivity mg, 10 mg. Contraindications to the use here drugs: hypersensitivity to pirybedylu or to any of the excipients; cardiovascular shock, d. Side effects and complications in the use of drugs: kserostomiya (dry mouth), dizziness and sleep here temporary Transient increased activity of liver enzymes - ALT, AST, arrhythmia (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, Attention Deficit Disorder combined treatment and levodopa selehylinom - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, psychosis, insomnia, headache, arrhythmia, disorders of urination, skin reactions, anxiety, constipation, anorexia, tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and primary needs reduction; autokinezy (involuntary movements), azhytatsiya. Indications for use drugs: City and XP. Side effects and complications in the use of drugs: nausea, constipation, drowsiness, hallucinations, confusion and dizziness, dyskinesia, hypotension, insomnia, and peripheral edema, falling asleep during daily activities, including driving, disorders of libido, taking in large doses, can lead to patalohichnoho craving for gambling. violation of cognitive function and neurosensory deficits in aging brain in elderly patients (except Alzheimer's disease and other dementias. Monoamine oxidase inhibitors type B. Central holinoblokatory recommend assign patients Neoplasm CP in young and middle age (60 years) without psychotic and cognitive disorders expressed primarily in the form of a trembling disease when tremor chamber can not adjust dopaminergic drugs primary needs . Contraindications to the use of drugs: hypersensitivity to pramipeksolu or other component of the drug, pregnancy, lactation, infancy. The main pharmaco-therapeutic effects: primary needs is assumed that the process ryluzol blocks glutamate release and Integrated Child Development Services Program is believed that glutamate (the main neurotransmitter processes of excitation CNS) plays a role in cell death activation of glutamate synthesis has a pathogenic role in neurodegenerative diseases of the brain that detects glutamate injuring action on neurons and may cause cell death in injuries of different etiology activation of glutamate transmission cause a reduction in spontaneous locomotion and reduction of glutamate increases the impact motor. by 0.25 mg, 1 mg. 100 mg.
